<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3440">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385810</url>
  </required_header>
  <id_info>
    <org_study_id>JDS_2020_13</org_study_id>
    <nct_id>NCT04385810</nct_id>
  </id_info>
  <brief_title>Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19</brief_title>
  <acronym>DOCOV</acronym>
  <official_title>Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The management of patients with SARS-CoV2 in respiratory distress can expose to corneal or&#xD;
      retinal lesions induced by the stay in intensive care.&#xD;
&#xD;
      Examination by ophthalmologists would make it possible to detect the most of the&#xD;
      ophthalmologic problems known in intensive care and to provide an early, preventive or&#xD;
      curative therapeutic response when possible, in order to avoid irreversible visual loss.&#xD;
&#xD;
      The object of the research is to assess the presence and the importance of surface&#xD;
      ophthalmologic lesions, the presence and the importance of retinal or optic nerve lesions, in&#xD;
      order to improve the monitoring and primary prevention of this population&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 27, 2020</start_date>
  <completion_date type="Actual">July 29, 2020</completion_date>
  <primary_completion_date type="Actual">July 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with direct exam at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Direct exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with direct exam at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Direct exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with direct exam at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Direct exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with direct exam at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Direct exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with slit lamp exam at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Slit lamp exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with slit lamp exam at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Slit lamp exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with slit lamp exam at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Slit lamp exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the cornea with slit lamp exam at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Slit lamp exam</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe tear film anomalies at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Shirmer test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe tear film anomalies at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Shirmer test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe tear film anomalies at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Shirmer test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe tear film anomalies at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Shirmer test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the retina at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the retina at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the retina at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the retina at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the optic nerve at day 0</measure>
    <time_frame>Day 0</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the optic nerve at day 7</measure>
    <time_frame>Day 7</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the optic nerve at day 14</measure>
    <time_frame>Day 14</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Describe ophthalmologic damage to the optic nerve at discharge of hospital</measure>
    <time_frame>Discharge of hospital, up to 3 months</time_frame>
    <description>Retinophotography</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Covid19</condition>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>Ophthalmologic exam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Ophthalmologic exam</intervention_name>
    <description>Direct exam and Slit lamp exam Shirmer test Retinophotography At inclusion, day 7, day 14 and discharge from hospital</description>
    <arm_group_label>Ophthalmologic exam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient SARS-CoV2 positive (RT-PCR or chest scanner)&#xD;
&#xD;
          -  hospitalized in intensive care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  traumatic lesion of the face or any other condition preventing any ophthalmological&#xD;
             evaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Michel DEVYS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Adolphe de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondation Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>April 29, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>November 13, 2020</last_update_submitted>
  <last_update_submitted_qc>November 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ophthalmological lesions</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

